SPECIAL REPORT
MOST SHARED
- How Boaz Weinstein and Hedge Funds Outsmarted JPMorgan
- Marc Faber: 100% Chance of Global Recession
- As Bank Loans Dry Up in Spain, Small and Medium Businesses Fight for Life
- How Nasdaq Lost Control of Facebook IPO, by the Minute
- RIM May Cut at Least 2,000 Jobs in Restructuring: Report
- JPMorgan Trading Loss: Did Regulators Miss the Risk?
- A New Look at the ‘New Poor’
- Six Pack: Beer Buzz of the Week
- Greek Exit Could Trigger 50% Fall in Euro Stocks: Analyst
- Under Pressure, FHA Skews to Wealthier Home Buyers
- Big Stock Upside for Hudson City Deal: Analyst
- 5 High-Yield Stocks Ready to Boost Dividends
- Yoshikami: Four Things You Need to Know About Gold Now
- Steinbock: The Euro Zone Endgame Begins
- Option Bulls Take Another Shot on Idenix
- How Nasdaq Lost Control of Facebook IPO, by the Minute
- Week Ahead: Europe Has Wall Street Bull on Short Leash
- Pro-Bailout Greeks Regain Lead in Polls Before Vote
- Citigroup Lost $20 Million on Facebook IPO Trades
- JPMorgan to Shake Up Risk Team After Big Loss: Report
- RIM May Cut at Least 2,000 Jobs in Restructuring: Report
- EU Finalizes Bank Reforms; Shifts Burden to Bondholders
- Spain's Bankia Eyes Stake Sales After Record Bailout
- EU Set to Launch Action Against China Over Telecom Aid
RSS FEED
Pharma's Market
Text Size 
Biotech Beats Pfizer
As I was Googling around looking for articles to use as homework for the upcoming Genentech meeting, I stumbled across this nugget on Matthew Herper's "Science Business" blog over at "Forbes."
When I wasn't looking the market value of biotech giant DNA [DNA
Loading...
()
] surpassed the market cap of the world's biggest drug company, Pfizer [PFE
Loading...
()
].
As I write this PFE is at $84 billion. And Genentech is at $90 billion.
And as Herper points out, Genentech's revenue is about a quarter of Pfizer's. What's more, a widely-expected higher bid from Swiss drugmaker Roche will drive the market cap of DNA even higher. Meantime there's little that analysts see on the horizon, aside from the stock being cheap, to move up PFE shares. The other Swiss drugmaker, Novartis, is nipping at Pfizer's heels with a market cap of nearly $83 billion.
Good catch, Matthew.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes
